VolitionRx Limited (NYSEAMERICAN:VNRX – Get Free Report)’s stock price passed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $0.00 and traded as high as $0.76. VolitionRx shares last traded at $0.73, with a volume of 44,624 shares traded.
VolitionRx Stock Down 1.1 %
The stock has a market capitalization of $43.75 million, a PE ratio of -1.24 and a beta of 1.59.
VolitionRx (NYSEAMERICAN:VNRX – Get Free Report) last released its earnings results on Wednesday, August 14th. The medical research company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.01. VolitionRx had a negative net margin of 9,158.31% and a negative return on equity of 15,493.47%. The firm had revenue of $0.40 million for the quarter, compared to the consensus estimate of $0.34 million. As a group, equities analysts anticipate that VolitionRx Limited will post -0.5 earnings per share for the current year.
VolitionRx Company Profile
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.
Recommended Stories
- Five stocks we like better than VolitionRx
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Why Fastenal Stock Could Hit New Highs After Strong Q3 Results
- How to Invest in the Best Canadian StocksÂ
- Why Eli Lilly Stock Is Soaring—and How It Plans to Stay on Top
- The Risks of Owning Bonds
- 3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside
Receive News & Ratings for VolitionRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRx and related companies with MarketBeat.com's FREE daily email newsletter.